Impact of empagliflozin in patients with diabetes and heart failure |
| |
Authors: | David Pham Natalia De Albuquerque Rocha Darren K McGuire Ian J Neeland |
| |
Institution: | 1. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd Dallas, TX 75390-8830;2. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX;3. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX |
| |
Abstract: | Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future. |
| |
Keywords: | Empagliflozin Heart failure SGLT2 inhibitor Type 2 diabetes mellitus CKD chronic kidney disease HF heart failure SGLT2 sodium glucose co-transporter 2 T2DM type 2 diabetes mellitus |
本文献已被 ScienceDirect 等数据库收录! |
|